Navigation Links
Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
Date:5/8/2008

ings (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD.

7. Wright C, Kramer ED, Zalman MA, et al. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend. 2006;83(Supp 1):S68-S76.


'/>"/>
SOURCE Alpharma Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
2. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
3. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
4. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
7. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
8. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
11. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)... III Trial Experience Better, Long-Term Clinical O...ents Treated with TAXUS,...-- Long-term data,presented for the first time tod...l trial studying the XIENCE(TM) V Everolimus Eluti... V continues to deliver clinically superior,benefi...
(Date:5/13/2008)... the Treatment of Inflammatory ...n Payment from Partner GlaxoSmithKline, MOUNTAIN ... Inc., today,announced the initiation of a Phase I...vel small molecule compound designed to specifical...ociated with inflammatory,diseases such as rheumat...
(Date:5/13/2008)...soluble polymer material,designed to stop bone ble...,according to a new animal study just published in...s come on the heels of recently published,research... the risk of,surgical infections., Researchers fr...rleston,and Keck School of Medicine at the Univers...
(Date:5/12/2008)...ion Prevention Business, DUBLIN, Ohio, May 12 /PR...rovider of products and services that improve the ...unced it has completed the,acquisition of assets o...f,infection prevention products sold under the Chl...cts are used widely in U.S. hospitals and,surgery ...
Breaking Medicine Technology:XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 2Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 3Cardinal Health Completes Enturia Acquisition 2Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 1Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 2Green Tea May Brew Up Healthier Skin 106 1Third Security LLC Hires Two New Managing Directors 110 1Third Security LLC Hires Two New Managing Directors 110 2Web Portal Makes Organ Donation Easy 108 1Web Portal Makes Organ Donation Easy 108 2
(Date:5/13/2008)...exercise helps prevent the disease, two additional...(HealthDay News) -- New research has found both ba...The bad news is a risk factor you can,t change: Wo...r face an increased risk of breast cancer througho...t diagnosis, according to a study in the May 13 is...
(Date:5/13/2008)...gress in patient safety research could slow to a c...issues, Johns Hopkins researchers assert in an upc...paradigm to patient safety research. It just isnt ...ctor for public health at the Johns Hopkins Berman...le. , The piece, published in the June issue of ...
(Date:5/13/2008)...mWater kicks off the summer with SYNERGY Events, ,...ve makeover competition, BOSTON, May 13 /PRNewswi... SYNERGY Events, the premier event planning compan...al live makeover competition. The,competition will...ns on May,16, 2008. Doors open at 8:30 p.m. at the...
(Date:5/13/2008)...AN ANTONIO, Texas, May 13 /PRNewswire/ -- Attorney...list Mormon community in Eldorado, TX,will ask a ...rgency order,to prevent the state from taking away... turns a year old on Thursday., Attorneys are fil...m.,seeking an emergency injunction to keep the Tex...
Breaking Medicine News(10 mins):Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 3Health News:Treating safety research like other clinical studies slows progress 2Health News:Treating safety research like other clinical studies slows progress 3Health News:TrimWater Keeps Boston Beautiful 2Health News:TrimWater Keeps Boston Beautiful 3Health News:FLDS Couple Seeks Emergency Order to Stop Infant Seizure, Say Perry & Haas 2Health News:FLDS Couple Seeks Emergency Order to Stop Infant Seizure, Say Perry & Haas 3
...ity of Texas feel that they may have found an effe...mor that threatens clear vision.// Using photodyna...ion in three patients who were suffering from intr...nvolved serious retinal detachments. Intraocular c...
...rom the University of California, they have observ...at a higher risk for developing Osteoarthritis. Os... causes pain in that area.// Osteoarthritis affect...s old. Experts estimate up to 70 percent of women ...
...hildren and teens with chronic fatigue syndrome ar...flexible joints than their healthy counterparts.//...in Baltimore examined 100 children, ages 10 and ol... evenly between patients diagnosed with CFS and ot...
...vely controlled with a higher dose of radiotherap...t for lung cancer involves a daily dose of radioth...r results have been found from a more intensive pr...ay for 12 days. Now researchers at the Mount Verno...
Other Medicine News:
Labcold platelet incubators provide accurate and stable storage conditions at 22C. Labcold have incorporated all of the same alarm, monitoring and recording functions that are found in the Labcold BS
Mini-Incubator PC100 is compact. It is the perfect solution for small institutions, mobile units, surgery rooms.
The PC2200h contains two shelves and will hold two PF96hi agitators. It can store 192 random bags (64 apheresis bags).
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis).
Medicine Products: